- Home
- RAPT vs MNKD Comparison
RAPT vs MNKD Comparison
Compare RAPT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAPT | MNKD |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | RAPT | MNKD |
|---|---|---|
| Price | $58.00 | $3.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $56.22 | $8.75 |
| AVG Volume (30 Days) | 4.1M | ★ 5.3M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $24.57 |
| Revenue Next Year | N/A | $14.12 |
| P/E Ratio | ★ N/A | $163.25 |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $0.71 | $2.94 |
| 52 Week High | $57.99 | $6.51 |
Technical Indicators
Market Signals| Indicator | RAPT | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 17.38 |
| Support Level | $32.00 | N/A |
| Resistance Level | N/A | $6.08 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | -0.79 | -0.30 |
| Stochastic Oscillator | 95.31 | 3.37 |
Price Performance
Historical ComparisonAbout RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.